Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine + sulfadiazine + folinate for ocular toxoplasmosis
jRCTs071180092Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pyrimethamine, Sulfadiazine and folinic acid in ocular toxoplasmosis and uveitis, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Fundus imaging improvement at 6 weeks or 4-6 weeks post-treatment. Started Apr 2020; status: recruiting.
02
Drugs
pyrimethamineSulfadiazinefolinic acid
03
Conditions
ocular toxoplasmosisuveitis
Beyond the preview
Go deeper on jRCTs071180092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180092.